Skip to content

Improved Diagnosis of Ovarian Cancer

Improved Diagnosis of Ovarian Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05842629
Enrollment
1700
Registered
2023-05-06
Start date
2021-05-15
Completion date
2028-12-31
Last updated
2024-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adnexal Carcinoma, Adnexal Lesion, Adnexal Mass, Adnexal Neoplasm, Ovarian Cancer, Ovarian Cysts, Ovarian Neoplasms

Brief summary

After implementation of systematic image description of adnexal masses, we aim to improve and evaluate our use of available imaging methods and biomarkers for classifying adnexal masses and distinguishing between benign and malignant adnexal masses in the hands of clinicians in Central Denmark Region. Secondarily, we want to improve our management of adnexal masses by evaluating the complications and longitudinal changes in conservatively managed adnexal masses. Data is registered prospectively but analyzed retrospectively.

Detailed description

Imaging methods include ultrasonography (US) by varied observers, Magnetic Resonance Imaging (MRI) and Positron Emission Tomography-Computed Tomography (PET-CT). Imaging criteria are based on recommendations by the International Ovarian Tumor Analysis (IOTA) group. Educational efforts in IOTA terminology and systematic description at ultrasonography may support quality in the diagnostic process. Patients will be diagnosed and treated according to national and regional guidelines by the local clinicians. The project has been evaluated by the Ethical Committee in the Central Denmark Region prior to initiation. The aim of the power calculation for estimation of sample size is to be able to detect a difference in sensitivity from 75% to 90% at a threshold of 200 for Risk of Malignancy Index (RMI) and 10% for Assessment of Different NEoplasia of the adneXa (ADNEX) model and two-step-strategy / The Ovarian-Adnexal Reporting and Data System (O-RADS). To detect a difference in sensitivity (90% for ADNEX and two-step-strategy vs 75% for RMI at a specificity of 80%) at least 103 cases of malignancy should be included (calculated by using paired proportions).

Interventions

None listed

Sponsors

Aarhus University Hospital
CollaboratorOTHER
Regionshospitalet Horsens
CollaboratorOTHER
Department of Gynaecology and Obstetrics, Viborg Regional Hospital
CollaboratorUNKNOWN
Department of Gynaecology and Obstetrics, Goedstrup Regional Hospital
CollaboratorUNKNOWN
Department of Gynaecology and Obstetrics, Randers Regional Hospital
CollaboratorUNKNOWN
University of Aarhus
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

Patients with an adnexal mass observed at ultrasonography.

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic efficiency of available imaging modalities by models and subjective evaluation for pre-operative diagnosis of adnexal masses6 monthsAccuracy measures for diagnosis of ovarian cancer: Sensitivity, specificity, positive and negative predictive values.
Area Under the Receiver Operating Characteristic Curve of ADNEX, O-RADS, two-step-strategy, Simple Rules and Risk of Malignancy Index.6 monthsComparison of AUC's between models/strategies

Secondary

MeasureTime frameDescription
Longitudinal changes in adnexal massesUp to 5 yearsChange in imaging characteristics, occurrence of malignancy
Complications in women with conservatively managed adnexal massesUp to 5 yearsIncidence of torsion, rupture, spontaneous resolution, surgeries.
Observer variability6 monthsInter- and intra observer variation

Countries

Denmark

Contacts

Primary ContactIna Marie Dueholm Hjorth, MD
imhjorth@gmail.com+004526192456

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026